Clear Street downgraded Y-mAbs Therapeutics (YMAB) to Hold from Buy with a price target of $8.60, down from $17, after the company agreed to be acquired by SERB Pharmaceuticals for $8.60 per share in cash. The firm expects the transaction to go through as announced and does not expect another bidder, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on YMAB:
- Y-mAbs Therapeutics downgraded to Hold from Buy at JonesResearch
- Palantir reports Q2 beat, Caterpillar posts mixed results: Morning Buzz
- Y-mAbs Therapeutics downgraded to Neutral from Outperform at Wedbush
- Y-Mabs Therapeutics Announces Merger with SERB Pharmaceuticals
- Y mAbs Therapeutics trading resumes